Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study

Asunercept (company code APG101 [Apogenix AG]; company code CAN008 [CANbridge Pharmaceuticals]) is a novel glycosylated fusion protein that has shown promising effectiveness in glioblastoma. This Phase I study was initiated to evaluate the tolerability and safety of asunercept in combination with st...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Kuo-Chen, Hsu, Peng-Wei, Tsai, Hong-Chieh, Lin, Ya-Jui, Chen, Ko-Ting, Toh, Cheng-Hong, Huang, Hui-Lin, Jung, Shih-Ming, Tseng, Chen-Kan, Ke, Yu-Xiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674255/
https://www.ncbi.nlm.nih.gov/pubmed/34911992
http://dx.doi.org/10.1038/s41598-021-02527-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674255/
https://www.ncbi.nlm.nih.gov/pubmed/34911992
http://dx.doi.org/10.1038/s41598-021-02527-1

Ejemplares similares